Combined LOH/CGH analysis proves the existence of interstitial 3p deletions in renal cell carcinoma

被引:72
作者
Alimov, A
Kost-Alimova, M
Liu, J
Li, CD
Bergerheim, U
Imreh, S
Klein, G
Zabarovsky, ER [1 ]
机构
[1] Karolinska Inst, Ctr Microbiol & Tumor Biol, S-17177 Stockholm, Sweden
[2] Russian Acad Sci, Engellhardt Inst Mol Biol, Moscow 117984, Russia
[3] Karolinska Hosp, Dept Urol, S-17176 Stockholm, Sweden
[4] Karolinska Inst, Ctr Genom Res, S-17177 Stockholm, Sweden
关键词
tumor suppressor genes; allele titration assay; deletion mapping; human chromosome 3;
D O I
10.1038/sj.onc.1203449
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
We have recently developed an allele titration assay (ATA) to assess the sensitivity and influence of normal cell admixture in loss of heterozygosity (LOH) studies based on CA-repeat, The assay showed that these studies are biased by the size-dependent differential sensitivity of allele detection. Based on these data, we have set up new criteria for evaluation of LOH, By combining these new rules with comparative genome hybridization (CGH) we have shown the presence of interstitial deletions in renal cell carcinoma (RCC) biopsies and cell lines, At least three out of 11 analysed RCC cell lines and three out of 37 biopsies contain interstitial deletions on chromosome 3, Our study suggests the presence of several regions on human chromosome 3 that might contribute to tumor development by their loss: (i) 3p25-p26, around the VHL gene (D3S1317); (ii) 3p21.3-p22 (between D3S1260 and D3S1611); (iii) 3p21.2 (around D3S1235 and D3S1289); (iv) 3p13-p14 (around D3S1312 and D3S1285), For the first time, AP20 region (3p21.3-p22) was carefully tested for LOH in RCC, It was found that the AP20 region is the most frequently affected area. Our data also suggest that another tumor suppressor gene is located near the VHL gene in 3p25-p26.
引用
收藏
页码:1392 / 1399
页数:8
相关论文
共 45 条
[41]   SOMATIC-CELL HYBRID PANEL AND NOTI LINKING CLONES FOR PHYSICAL MAPPING OF HUMAN-CHROMOSOME-3 [J].
WANG, JY ;
ZABAROVSKY, ER ;
TALMADGE, C ;
BERGLUND, P ;
CHAN, KWK ;
POKROVSKAYA, ES ;
KASHUBA, VI ;
ZHEN, DK ;
BOLDOG, F ;
ZABAROVSKAYA, VI ;
KISSELEV, LL ;
STANBRIDGE, EJ ;
KLEIN, G ;
SUMEGI, J .
GENOMICS, 1994, 20 (01) :105-113
[42]  
Wei MH, 1996, CANCER RES, V56, P1487
[43]  
WILHELM M, 1995, CANCER RES, V55, P5383
[44]  
YAMAKAWA K, 1991, CANCER RES, V51, P4707
[45]  
YANO H, 1988, IN VITRO CELL DEV B, V24, P9